Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
ABSTRACT Ritlecitinib is a kinase inhibitor drug recently approved for the treatment of alopecia areata (AA) in both adults and adolescents based on a single, combined Phase 2b/3 study. Various QD doses with and without a loading dose have been evaluated in the pivotal Phase 2b/3 study. Therefore, c...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/psp4.70030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|